Download PDF
Aktuelle Kardiologie 2015; 4(3): 169-174
DOI: 10.1055/s-0035-1546007
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Neues zur medikamentösen und interventionellen Therapie bei Herzinsuffizienz

News to Medical and Interventional Therapy in Heart Failure
Y. Linicus
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar
,
I. Kindermann
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar
,
D. Lavall
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar
,
M. Böhm
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar
› Author Affiliations
Further Information

Publication History

Publication Date:
15 June 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Herzinsuffizienz ist eine der häufigsten chronischen Erkrankungen weltweit und mit einer hohen Morbidität und Mortalität vergesellschaftet. Aufgrund dieser Erkrankung entstehen weltweit jährlich Kosten in Höhe von mehreren Milliarden Euro, 60–70 % aufgrund von Behandlungskosten durch Krankenhausaufenthalte. Neben einer maximalen medikamentösen Behandlung kommen immer mehr interventionelle Methoden und Device-Therapien bei Herzinsuffizienz zum Einsatz.

Abstract

Heart failure ranks amongst the commonest causes of morbidity and mortality due to chronic disease. It is estimated that heart failure leads to costs of several billion euro worldwide, with 60–70 % as direct costs for hospitalization. In addition to a maximum drug treatment more interventional methods and device therapy in heart failure come to use.

Schlüsselwörter

akute und chronische Herzinsuffizienz - ESC Guidelines - Ivabradin - Aldosteronantagonisten - MitraClip - LCZ696 - Neuromodulation

Key words

acute and chronic heart failure - ESC guidelines - Ivabradin - aldosteron antagonism - MitraClip - LCZ696 - neuromodulation
 

  • Literatur

  • 1 McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869
    CrossrefPubMedGoogle Scholar
  • 2 Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
    Google Scholar
  • 3 Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
    Google Scholar
  • 4 Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
    Google Scholar
  • 5 Chatterjee S, Moeller C, Shah N et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012; 125: 817-825
    CrossrefPubMedGoogle Scholar
  • 6 Pitt B, Pfeffer MA, Assmann SF et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392
    CrossrefPubMedGoogle Scholar
  • 7 Pfeffer MA, Claggett B, Assmann SF et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015; 131: 34-42
    Google Scholar
  • 8 Nanchen D, Leening MJ, Locatelli I et al. Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study. Circ Heart Fail 2013; 6: 403-410
    CrossrefPubMedGoogle Scholar
  • 9 Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
    CrossrefPubMedGoogle Scholar
  • 10 Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22
    CrossrefPubMedGoogle Scholar
  • 11 Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894
    CrossrefPubMedGoogle Scholar
  • 12 McMurray JJ, Adamopoulos S, Anker SD et al. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
    CrossrefPubMedGoogle Scholar
  • 13 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
    CrossrefPubMedGoogle Scholar
  • 14 McMurray JJ, Packer M, Desai AS et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004
    CrossrefPubMedGoogle Scholar
  • 15 Piérard LA, Carabello BA. Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment. Eur Heart J 2010; 31: 2996-3005
    CrossrefPubMedGoogle Scholar
  • 16 Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet 2009; 373: 1382-1394
    CrossrefPubMedGoogle Scholar
  • 17 Feldman T, Kar S, Rinaldi M et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009; 54: 686-694
    CrossrefPubMedGoogle Scholar
  • 18 Feldman T, Foster E, Glower DD et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406
    CrossrefPubMedGoogle Scholar
  • 19 Mauri L, Foster E, Glower DD et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 2013; 62: 317-328
    CrossrefPubMedGoogle Scholar
  • 20 Franzen O, van der Heyden J, Baldus S et al. MitraClip® therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 2011; 13: 569-576
    CrossrefPubMedGoogle Scholar
  • 21 Singh JP, Kandala J, Camm AJ. Non-pharmacological modulation of the autonomic tone to treat heart failure. Eur Heart J 2014; 35: 77-85
    CrossrefPubMedGoogle Scholar
  • 22 Li M, Zheng C, Sato T et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004; 109: 120-124
    PubMedGoogle Scholar
  • 23 De Ferrari GM, Crijns HJ, Borggrefe M et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011; 32: 847-855
    CrossrefPubMedGoogle Scholar
  • 24 Zannad F, De Ferrari GM, Tuinenburg AE et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015; 36: 425-433
    CrossrefPubMedGoogle Scholar
  • 25 Bakris GL, Nadim MK, Haller H et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152-158
    CrossrefPubMedGoogle Scholar
  • 26 Gronda E, Seravalle G, Brambilla G et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014; 16: 977-983
    CrossrefPubMedGoogle Scholar
  • 27 Halbach M, Hickethier T, Madershahian N et al. Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction. Expert Rev Cardiovasc Ther 2014; 12: 1465-1469
    CrossrefPubMedGoogle Scholar
  • 28 Abraham WT, Zile MR, Weaver FA et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015; DOI: 10.1016/j.jchf.2015.02.006.
    PubMedGoogle Scholar
  • 29 Krum H, Sobotka P, Mahfoud F et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209-215
    CrossrefPubMedGoogle Scholar
  • 30 Symplicity HTN-2 Investigators. Esler MD, Krum H et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909
    CrossrefPubMedGoogle Scholar
  • 31 Davies JE, Manisty CH, Petraco R et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013; 162: 189-192
    CrossrefPubMedGoogle Scholar